In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Karyopharm Therapeutics

http://www.karyopharm.com/

Latest From Karyopharm Therapeutics

Xpovio’s Solid Tumor Debut Faces Likely Three-Year Delay

Karyopharm will conduct another trial of the drug in p53 wild-type endometrial cancer after the FDA said SIENDO data were insufficient for approval.

Cancer FDA

Subgroup Could Give Xpovio Focused Commercial Opportunity In Endometrial Cancer

Karyopharm’s Phase III SIENDO study showed what analysts called a “modest” progression-free survival improvement overall, but a fourfold improvement in patients with wild-type p53.

Cancer Business Strategies

Oncology Dominates China's 43 New Approvals In 2021, Domestics Emerge To Lead Innovation

Out of the more than 40 approvals granted to new drugs in China in 2021, domestic companies bagged around half to catch up with their multinational peers in the annual innovation scorecard.

China Approvals

Deal Watch: Roche, Pfizer, GSK Close Out 2021 With Licensing Transactions

Ahead of the usual flurry of deal-making in January, Roche gets retinal cell therapy candidate from Lineage Cell Therapeutics, Pfizer subsidiary Amplyx licenses antiviral candidate to Vera, and GSK expands neurology tie-up with Ligand.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • NPM Pharma, Inc.
UsernamePublicRestriction

Register